Liquidia (LQDA) to Release Earnings on Thursday

Liquidia (NASDAQ:LQDA) is projected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Liquidia to post earnings of $0.34 per share and revenue of $116.6210 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business had revenue of $92.02 million for the quarter, compared to analysts’ expectations of $87.49 million. Liquidia’s revenue was up 3072.4% on a year-over-year basis. On average, analysts expect Liquidia to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Liquidia Trading Up 1.5%

LQDA opened at $40.74 on Wednesday. The business has a fifty day moving average price of $36.60 and a 200 day moving average price of $34.44. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. Liquidia has a 12 month low of $11.85 and a 12 month high of $46.67. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of -49.06 and a beta of 0.41.

Insiders Place Their Bets

In related news, CAO Dana Boyle sold 1,576 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $37.78, for a total value of $59,541.28. Following the completion of the sale, the chief accounting officer directly owned 175,342 shares of the company’s stock, valued at $6,624,420.76. This represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Adair sold 688 shares of Liquidia stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $41.65, for a total value of $28,655.20. Following the transaction, the insider directly owned 214,738 shares in the company, valued at approximately $8,943,837.70. This trade represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 578,820 shares of company stock worth $22,746,258. Corporate insiders own 25.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. TCG Crossover Management LLC purchased a new stake in shares of Liquidia in the third quarter valued at about $38,887,000. MPM Bioimpact LLC grew its holdings in shares of Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in Liquidia in the 3rd quarter valued at about $12,571,000. Invesco Ltd. raised its stake in Liquidia by 428.3% during the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after acquiring an additional 341,009 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in Liquidia during the 4th quarter valued at approximately $10,587,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LQDA has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Zacks Research downgraded shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, BTIG Research raised their price target on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).